PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis

Peer Review reports

Original Submission
3 Nov 2022	Submitted	Original manuscript
15 Nov 2022	Author responded	Author comments - Chuhan Chung
8 Dec 2022	Reviewed	Reviewer Report
15 Dec 2022	Reviewed	Reviewer Report - Debjyoti Kundu
Resubmission - Version 2
15 Nov 2022	Submitted	Manuscript version 2
Publishing
13 Jan 2023	Editorially accepted
15 Mar 2023	Article published	10.1186/s12876-023-02653-2

Back to article page